4D Molecular Therapeutics (FDMT) EBT Margin (2020 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed EBT Margin for 6 consecutive years, with 63172.22% as the latest value for Q3 2025.
- On a quarterly basis, EBT Margin rose 139822778.0% to 63172.22% in Q3 2025 year-over-year; TTM through Sep 2025 was 174284.17%, a 66931583.0% increase, with the full-year FY2024 number at 434570.27%, down 43408455.0% from a year prior.
- EBT Margin was 63172.22% for Q3 2025 at 4D Molecular Therapeutics, up from 363980.0% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 169847.37% in Q4 2023 to a low of 4965000.0% in Q4 2024.
- A 5-year average of 416806.58% and a median of 12394.98% in 2023 define the central range for EBT Margin.
- Peak YoY movement for EBT Margin: crashed -513484737bps in 2024, then surged 139822778bps in 2025.
- 4D Molecular Therapeutics' EBT Margin stood at 27256.52% in 2021, then surged by 92bps to 2194.07% in 2022, then surged by 7841bps to 169847.37% in 2023, then tumbled by -3023bps to 4965000.0% in 2024, then skyrocketed by 99bps to 63172.22% in 2025.
- Per Business Quant, the three most recent readings for FDMT's EBT Margin are 63172.22% (Q3 2025), 363980.0% (Q2 2025), and 343135.71% (Q1 2025).